🇺🇸 FDA
Patent

US 11884919

Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene

granted A61KA61K31/713A61P

Quick answer

US patent 11884919 (Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene) held by Alnylam Pharmaceuticals, Inc. expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/713, A61P, A61P1/00, A61P1/04